Analyzing a set of 194 patents on ‘Citalopram’ using Patent iNSIGHT Pro - CHEMPAT Edition

Sales Contact:

sales@patentinsightpro.com

+1-866-716-1507
+44-20-32862300
+91.22.32208312

Patent iNSIGHT Pro
Transform Patents to Intelligence



Extract the chemical structures (based on generic, IUPAC and brand names) using CHEMPAT Extractor


CHEMPAT Extractor
Extract Chemicals
Extract chemical names and structure from records
Settings:
Ignore Chemical Names
Edit Chemical Names
Supply Ignore List from file. (CSV / TXT)
New Records Only
All Records
Extract Chemical From
Title & Abstract
Claims
Description
Chemical Names
Information
We can supply the ignore list of the chemical names which should not be picked during the process of chemical extraction.
We can select the sections of the patents from where we would like to extract the chemical structures.


citalopram_2007-08-28 01:03:45 - [Patent iNSIGHT Pro - CHEMPAT Full Edition]
File Tools Help
Close Report
Add Patents
Cleanup Tools
Analytics Tools
Report Last Indexed on - November 01,2010
Reindex Now
Custom Fields
Identify Families
CHEMPAT Viewer
Portfolio Cluster Engine
Advanced Search
Natural Language Search
Similarity Search
Word Search
Reports Dashboard
Co-occurrence Analyzer
Citation Analysis
VizMAP
360° Report
Excel Report-Mapping
PDF Downloader
Equivalent Portfolio
Export Patents
Refresh
F/R Scor... Patent No Assignee
EP0171943 Novel intermediat LUNDBECK & CO AS H
EP0347066 New enantiomers LUNDBECK & CO AS H
EP0474580 Use of 1-[3-(dime phenylphthalenes cerebrovascular c LUNDBECK & CO AS H
EP0714663 Potentiation of dr receptor antagoni LILLY CO ELI
EP1095926 Production metho compound, interm method of the inte SUMIKA FINE CHEMICALS CO LTD
EP1125907 Intermediates for SUMIKA FINE CHEMICALS CO LTD
EP1152000 Citalopram hydrob crystallization ther SUMIKA FINE CHEMICALS CO LTD
EP1169314 CRYSTALLINE B LUNDBECK & CO AS H
EP1288211 Improved process citalopram hydrob GEKHSARIA CHEMICALS LTD
EP1486492 A process for hyd dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran. SUN PHARMACEUTICALS IND LTD;SUN PHARMACEUTICALS INDUSTRIES LTD;SUN PHARMACEUTICALS INDUSTRIES LTDSUN PHARMACEUTICALS IND LTD
EP1502907 A process for the preparation of (2-hydroxymethyl-phenyl)-phenyl-methanol derivatives SYNTECO S P A
EP1726298 Oral liquid formulations containing citalopram ERREKAPPA EUROTERAPICI S P A
EP1777221 Process for the preparation of 5-cyanophthalide starting from 5-carboxyphthalide ADORKEM TECHNOLOGY SPA
GB2376233 Crystals of a pharmaceutically acceptable salt of citalopram wherein the median particle size of the crystals is at least 40 microns LUNDBECK & CO AS H
GB2376945 Citalopram preparation CIPLA LTD
GB2392385 Pharmaceutical preparations comprising a 5HT uptake inhibitor and a homopolymer or copolymer of N-vinyl pyrrolidone CIPLA LTD
JP2001106681 METHOD FOR PRODUCING 5-CYANOPHTHALIDE, AND METHOD FOR PRODUCING INTERMEDIATE FOR THE SAME SUMIKA FINE CHEMICALS CO LTDSUMIKA FINE CHEMICALS CO LTD
JP2001114773 PHTHALAN COMPOUND, ITS INTERMEDIATE, METHOD FOR PRODUCING THE SAME AND METHOD FOR PRODUCING CITALOPRAM SUMIKA FINE CHEMICALS CO LTDSUMIKA FINE CHEMICALS CO LTD
JP2002114770 METHOD OF PRODUCING CITALOPRAM, SUMIKA FINE CHEMICALS CO
Auto Filter
-- Select Filter ---
Apply Filter
Clear Filter
- Select -
Plot
Segment by : Assignee
-- Split --
LUNDBECK &...
PETERSEN H...
PETERSEN, ...
H LUNDBECK...
AHMADIAN H...
CIPLA LTD
NATCO PHAR...
ADORKEM TE...
AHMADIAN, ...
SUMITOMO C...
DANCER ROB...
DANCER, RO...
H. LUNDBEC...
HAMIED YUS...
HAMIED, YU...
JUBILANT O...

CHEMPAT Viewer

View By Record | View By Chemical Name | View By TAC

Search Type: SUBSTRUCTURE

Search In: TA Claims Desc

Search By : Chemical Name | Chemical Structure

Enter chemical name | Search | Create Chemical Structure

Total Patents - **194**

Unique Chemical Count : **20**

Selected Chemical : -

#	G...	Record No	Title	Assignee
1		EP0171943	Novel intermediate and method for its preparation.	LUNDBECK & CO AS H
2		EP0347066	New enantiomers and their isolation.	LUNDBECK & CO AS H
3		EP0474580	Use of 1-[3-(dimethylamino)propyl]-1-phenylphthalenes for the treatment of cerebrovascular disorders.	LUNDBECK & CO AS H
4		EP0714663	Potentiation of drug response by a serotonin 1A receptor antagonist	LILLY CO ELI
5		EP1095926	Production method of 5-phthalancarbonitrile compound, intermediate therefor and	SUMIKA FINE CHEMICALS CO LTD
			citalopram	
		EP1152000	Citalopram	SUMIKA FINE CHEMICALS CO

Molecule	Molecule	Molecule
4-(2-hydroxy-3-cyclohexylami...	alkene	alkyne
		
alprenolol	carbon	citalopram
		
dopamine	fluvoxamine	hydroxy
		

View by record: we can click on the patent of our interest to see all the structures present in the body of the patent.


CHEMPAT Viewer
View By Record
View By Chemical Name
View By TAC
Search Type: SUBSTRUCTURE
Search In: TA Claims Desc
Search By :
Chemical Structure
Create Chemical Structure
Total Chemicals - 796
Patent Count : 2 for (hydroxymethyl)-benzonitrile
Clicking on this will give us the hit details.
Chemical Name
1 (2-hydroxymethyl-phenyl)-phenyl-methanol 1
2 (4 fluorophenyl)-(2-chloromethyl-4-cyanophenyl) metha 1
3 (4-amino- 5-chloro-2-methoxyphenyl) -3-[1- [2- [(methylsulfonyl) amino] ethyl] -4-piperidinyl] 1
4 (4-bromo-2- (hydroxymethyl) phenyl)-(4-fluorophenyl) methanol 1
5 (4-bromo-2-(hydroxymethyl)phenyl)-(4-fluorophenyl)methanol 1
6 (4-cyano-2-hydroxymethylphenyl) (4-fluorophenyl) methanol 1
7 (4-fluoro benzoyl) benzonitrile 1
8 (4-fluorophenyl) methanol 1
9 (4-fluorophenyl)-1, 3-dihydro-5-isobenzofurancarbonitrile 1
10 (4-fluorophenyl)-1, 3-dihydro-5-isobenzofurancarbonitrile 1
11 (4-fluorophenyl)-1-hydroxy- 1
12 (4-isobutylphenyl) propionyl chloride 1
13 (dimethylamino)- 1- (4-fluorophenyl)- 1
14 (hydroxymethyl)-benzonitrile 2
15 (s)- 1
16 (s)-2- (6-methoxynaphth-2-yl)-propionyl chloride 1
17 (s)-citalopram 1
18 (s)-n-acetyl-alanine 1
(trifluoromethyl)-2h-1-benzopyran-3-carb
G... Record No Title Abstract Filling date Ass
WO03000672 PROCESS FOR THE PREPARATION OF RACEMIC CITALOPRAM AND/OR S- OR R-CITALOPRAM BY SEPARATION OF A MIXTURE OF R- AND S-CITALOPRAM The invention relates to a process for the preparation of racemic citalopram free base or an acid addition salt thereof and/or R- or S-citalopram as the free base or an acid addition salt thereof by separation of a mixture of R- and S-citalopram with more than 50% of one of the enantiomers into a fraction consisting of racemic citalopram and/or a fraction of S-citalopram or R-citalopram characterized in that i) citalopram is precipitated from a solvent as the free base or as an acid addition salt thereof; ii) the precipitate formed is separated from the mother liquor; iia) if the precipitate is crystalline it is optionally recrystallised one or more times to form racemic citalopram, and then optionally converted into an acid addition salt thereof; iib) if the precipitate is not crystalline, steps i) and ii) are optionally repeated until a crystalline precipitate is obtained and the crystalline precipitate is recrystallised one or more times to form racemic citalopram, and then optionally converted into an acid addition salt thereof; iii) the mother liquor is optionally subjected to further purification and S-citalopram or 2002-06-25
We can view the patents even by chemical names.

Showing content for Hits

... PN: WO03000672 AN: CHRISTENSEN TROELS VOLSGAARD,CHRISTENSEN, TROELS, VOLSGAARD,DANCER ROBERT,DANCER, ROBERT,HUMBLE RI EVA,HUMBLE, RIKKE, EVA,LUNDBECK & CO AS H,NIELSEN OLE,NIELSEN, OLE,PETERSEN HANS,PETERSEN, HANS,ROCK MICHAEL HAROLD,ROCK, MICHAEL, HAROLD TTL: PROCESS FOR THE PREPARATION OF RACEMIC CITALOPRAM AND/OR S- OR R-CITALOPRAM BY SEPARATION...

... described under step i) before isolation of the R-or S-citalopram from the mother liquor. 11. The process according to claims 1-9 characterised in that a mixture of S-citalopram with more than 50 % of the S-enantiomer is prepared from a mixture of R-and S-4- [4- (dimethylamino)-1- (4-fluorophenyl)-1-hydroxybutyl]-3 (hydroxymethyl)-benzonitrile with more than 50% of the S-enantiomer by formation of a labile ester group and thereafter ring closure in a basic environment. 12. The according to claims 1-6 and 8-9 characterised in that a mixture of R-and S-citalopram with more than 50 % of the R-enantiomer is prepared from a mixture of R-and (dimethylamino)- 1- (4-fluorophenyl)- I-hydroxybutyl]-3-(hydroxymethyl)-benzonitrile with more than 50% of the R-enantiomer by formation of a labile ester group a thereafter ring closure in a basic environment. 13. The process according to claims 1-9 characterised in that a mixture of Rand S-citalopram with more than 50 % of t S-enantiomer...

... is prepared from a mixture of R-and S-4- [4- (dimethylamino)-1- (4-fluorophenyl)-1-hydroxybutyl]-3 (hydroxymethyl)-benzonitrile with more than 50% of the R-enantiomer by ring closure in presence of an acid. 14. The process according to claims 1-6 and 8-9 characterised in that mixture of R-and S-citalopram with more t % of the R-enantiomer is prepared from a mixture of R-and S-4- [4- (dimethylamino)-1- (4-fluorophenyl)-1-hydroxybutyl]-3- (hydroxymethyl)-benzonitrile with more 50% of the S-enantiomer by ring closure in presence of an acid. 15. A process for the preparation of a mixture or R-and S citalopram with more than 50 % of the S-enantiomer characterised in that a mixture of R-and S-4- [4

... more than 50% of the S-enantiomer is subjected to ring closure in presence of an acid. 17. The process according to claims 12,13 or 15 characterised in that the st material contain more than 90% of R-4- [4- (dimethylamino)-1- (4- fluorophenyl)-1-hydroxybutyl]-3- (hydroxymethyl)-benzonitrile compared to S-4- [4 (dimethylamino (4-fluorophenyl)-1-hydroxybutyl]-3- (hydroxymethyl)benzonitrile. 18. The process according to claims 13-16 characterised in that the acid used in the ring-closure rea a mineral acid, a carboxylic acid, a sulfonic acid or sulfonic acid derivative. 19. The process according to claim 18...

CHEMPAT Viewer

View By Record | View By Chemical Name | View By TAC

Search Type: SUBSTRUCTURE

Search In: TA Claims

Search By : Chemical Name | Chemical Structure

Enter chemical name | Search | Create Chemical Structure

Total Patents - **194**

#	G...	Record No	Title	Assignee
1		EP0171943	Novel intermediate and method for its preparation.	LUNDBECK & CO AS H
2		EP0347066	New enantiomers and their isolation.	LUNDBECK & CO AS H
3		EP0474580	Use of 1-[3-(dimethylamino)propyl]-1-phenylphthalenes for the treatment of cerebrovascular disorders.	LUNDBECK & CO AS H
4		EP0714663	Potentiation of drug response by a serotonin 1A receptor antagonist	LILLY CO ELI
5		EP1095926	Production method of 5-phthalancarbonitrile compound, intermediate therefor and production method of the	SUMIKA FINE CHEMICALS CO LTD

TAC

TTL , ABST & CLAIMS
2. A production method of a compound of the formula [I]
EMI43.2
which comprises converting 4-bromofluorobenzene to 4-fluorophenylmagnesium bromide, and reacting the 4-fluorophenylmagnesium bromide with 2,4-dimethylbenzaldehyde. 3. A production method of a compound of the formula [II]
EMI43.3
which comprises oxidizing a compound of the formula [I]
EMI43.4
4. A production method of 1,3-dimethyl-4-(4-fluorobenzoyl)benzene, which comprises subjecting m-xylene as a starting material and solvent to Friedel-Crafts reaction with 4-fluorobenzoyl halide. 5. A production method of a compound of the formula [II]
EMI44.1

Molecule	Molec
1,3-dimethyl-4-...	4-fluorob
	
benzene	m-xyle
	

View by TAC: we can see the structures represented by each section of the patent by moving the cursor on the particular section of the patent.

We can edit or draw a structure and save it in various formats on our HD for future use.

MarvinSketch

File Edit View Insert Atom Bond Structure Tools Help

100%



2D

Save

Save In: Desktop

GEXCEL
Gridlogics
INDIAN p
IP address
Journals
MySQL
Picasa3
Ppro backup restore
Pre requisites

ChemAxon Marvin Documents / MRV (*.mrv)
ChemAxon Extended SMILES / cxsmiles (*.cxsmiles *.cxsmi)
ChemAxon Extended SMARTS / cxsmarts (*.cxsmarts *.cxsma)
ChemAxon SMILES Abbreviated Groups (*.abbrevgroup)
ChemAxon Compressed Molfile (*.csmol)
ChemAxon Compressed SDfile (*.cssdf *.t)
ChemAxon Compressed RDfile (*.csrdf)
MDL Molfile (*.mol)

File Name:

Files of Type: ChemAxon Marvin Documents / MRV (*.mrv)

			antagonist
5		EP1095926	Production method of 5-phthalanca nitrile compound, intermediate therefor and production method of the
6		EP1125907	Intermediates the productio citalopram
		EP1152000	Citalopram

TL , ABST & CLAIMS

ethod of a compound of the formula [I]

converting 4-bromofluorobenzene to gnesium bromide, and reacting the gnesium bromide with ldehyde. 3. A production method of a ormula [II]

Molecule

4-fluorob

benzene

m-xyle


w By Record
View By Chemical Name
View By TAC
rch Type
SUBSTRUCTURE
Search By
Chemical Name
Enter chemical name
Search
Refresh
Search In:
TA
Claims
Desc
Chemical Structure
Create Chemical Structure
Create New Structure
File Edit View Insert Atom Bond Structure Tools Help
100%
H C N O S F P Cl Br I
Molecule
romofluorobenzene
anhydride
R
R1
Substructure searching is possible using the chemical structure search option.
EP1152000
Citalopram hydrobromide
SUMIKA FINE CHEMICALS CO LTD

CHEMPAT Viewer

View By Record | View By Chemical Name | View By TAC

Search Type: SUBSTRUCTURE

Search In: TA Claims Desc

Search By : Chemical Name | Chemical Structure

Enter chemical name | Search | Clear

Total Patents - **118**

Unique Chemical Count : **1**

Selected Chemical : -

#	G...	Record No	Title	Assignee
1		EP0474580	Use of 1-[3-(dimethylamino)propyl]-1-phenylphthalenes for the treatment of cerebrovascular disorders.	LUNDBECK & CO AS H
2		EP0714663	Potentiation of drug response by a serotonin 1A receptor antagonist	LILLY
3		EP1125907	Intermediates for the production of citalopram	SUMIKA FINE CHEMICALS CO LTD
4		EP1152000	Citalopram hydrobromide crystal and method for crystallization thereof	SUMIKA FINE CHEMICALS CO LTD
5		EP1169314	CRYSTALLINE BASE OF CITALOPRAM	LUNDBECK & CO AS H
6		EP1288211	Improved process for the manufacture of citalopram hydrobromide from 5-bromophthali	SEKHSARIA CHEMICALS LTD
		EP1726298	Oral liquid	ERREKAPPA EUROTERAPICI

LUNDBECK & CO AS H

Molecule	Molecule	Molecule
citalopram		



Results after doing substructure search in the set of 194 patents.

CHEMPAT Viewer

View By Record | View By Chemical Name | View By TAC

Search Type: SUBSTRUCTURE

SUBSTRUCTURE
SUPERSTRUCTURE
DUPLICATE
FULL
FULL_FRAGMENT

Search By : Chemical Name — Enter chemical name — Search

Chemical Structure — Create Chemical Structure

Unique Chemical Count: 94

Selected Chemical : -

#	G...	Record No	Title	Assignee
1		EP0171943	Novel intermediate and method for its preparation.	LUNDBECK & CO AS H
2		EP0347066	New enantiomers and their isolation.	LUNDBECK & CO AS H
3		EP0474580	Use of 1-[3-(dimethylamino)propyl]-1-phenylphthalenes for the treatment of cerebrovascular disorders.	LUNDBECK & CO AS H
4		EP0714663	Potentiation of drug response by a serotonin 1A receptor antagonist	LILLY CO ELI
5		EP1095926	Production method of 5-phthalancarbonitrile compound, intermediate	SUMIKA FINE CHEMICALS CO LTD
6			the production of citalopram	LTD
		EP1152000	Citalopram	SUMIKA FINE CHEMICALS CO

Mole	Molecule	Molecule
4-(2-hydroxy-3-(...hexylami...	alkene	alkyne
		
alprenolol	carbon	citalopram
		
dopamine	fluvoxamine	hydroxy
		
methyl group	norepinephrine	paroxetine
		

Similarly one can do chemical name search also within the set of patents.

Various options available in chemical structure searching.

Patent Viewer

Detailed View | Tabular View | Family View

GB2392385: Pharmaceutical preparations comprising a 5HT uptake inhibitor and a homopolymer or copolymer of N-vinyl pyrrolic

Search: Advanced Search Mode Enabled Look In: All

Right click on patent in Patent List to add patent in UDC or to set Scores

Patent List:

EP0171943
EP0347066
EP0474580
EP0714663
EP1095926
EP1125907
EP1152000
EP1169314
EP1288211
EP1486492
EP1502907
EP1726298
EP1777221
GB2376233
GB2376945
GB2392385
JP2001106681
JP2001114773
JP2002114770

Biblio | Claims | Description | Family | Legal Status | Other | Custom Fields

Edit Title Abstract

Patent No.: GB2392385

Title: Pharmaceutical preparations comprising a 5HT uptake inhibitor and a homopolymer or copolymer of N-vinyl pyrrolidone

Score1(Global): ---

Abstract: Pharmaceutically acceptable preparations comprising one or more 5HT uptake inhibitors with an excipient matrix comprising a homopolymer or copolymer of N-vinyl pyrrolidone in which the 5HT uptake inhibitors are complexed with the homopolymer or copolymer. The 5HT uptake inhibitors are preferably in amorphous form and may be selected from citalopram, venlafaxine, desmethyl venlafaxine, sertraline, fluoxetine and their salts. The homopolymer or copolymer is preferably a polyvinylpyrrolidone or crospovidone. The preparations are suitable for the treatment of a range of diseases which are prevented, ameliorated or eliminated by the administration of a 5HT uptake inhibitor. Such diseases include depression, substance abuse and senile dementia. One or more 5HT uptake inhibitors together with a homopolymer or copolymer of N-vinyl pyrrolidone may be used in the treatment of such diseases

PDF | Image | Claims Tree | Chem.Structure | Search Results

Refresh Find

PN:	GB2392385
AN:	CIPLA LTD
TTL:	Pharmaceutical preparations comprising a 5HT uptake inhibitor and a homopolymer or copolymer of N-vinyl pyrrolidone
ABST:	Pharmaceutically acceptable preparations comprising one or more 5HT uptake inhibitors with an excipient matrix comprising a homopolymer or copolymer of N-vinyl pyrrolidone in which the 5HT uptake inhibitors are complexed with the homopolymer or copolymer. The 5HT uptake inhibitors are preferably in amorphous form and may be selected from citalopram, venlafaxine, desmethyl venlafaxine, sertraline, fluoxetine and their salts. The homopolymer or copolymer is preferably a polyvinylpyrrolidone or crospovidone. The preparations are suitable for the treatment of a range of diseases which are prevented, ameliorated or eliminated by the administration of a 5HT uptake inhibitor. Such diseases include depression, substance abuse and senile dementia. One or more 5HT uptake inhibitors together with a homopolymer or copolymer of N-vinyl pyrrolidone may be used in the treatment of such diseases
CLM:	
PEC:	
CMT:	
UDC1:	citalopram, Formulation

Chemical Structure

citalopram



In 'chemical structure viewer' (patent viewer) one can just keep cursor on the chemical names of interest and see the structure.

Comments:


iled View
Tabular View
Family View
GB2392385: Pharmaceutical preparations comprising a 5HT uptake inhibitor and a homopolymer or copolymer of N-vinyl pyrrolidone
Search:
Advanced Search Mode Enabled
Look In:
All
click on patent in Patent List to add patent in UDC or to set Scores
ent List:
171943
347066
474580
714663
095926
125907
152000
169314
288211
486492
502907
726298
777221
376233
376945
392385
001106681
001114773
002114770
002371077
003040882
0020187929
0030208687
ily Members:
how Family
Biblio
Claims
Description
Family
Legal Status
Other
Custom Fields
Edit
Title
Abstract
Patent No.: GB2392385
Title: Pharmaceutical preparations comprising a 5HT uptake inhibitor and a homopolymer or copolymer of N-vinyl pyrrolidone
Score1(Global): ---
Abstract: Pharmaceutically acceptable preparations comprising one or more 5HT uptake inhibitors with an excipient matrix comprising a homopolymer or copolymer of N-vinyl pyrrolidone in which the 5HT uptake inhibitors are complexed with the homopolymer or copolymer. The 5HT uptake inhibitors are preferably in amorphous form and may be selected from citalopram, venlafaxine, desmethyl venlafaxine, sertraline, fluoxetine and their salts. The homopolymer or copolymer is preferably a polyvinylpyrrolidone or crospovidone. The preparations are suitable for the treatment of a range of diseases which are prevented, ameliorated or eliminated by the administration of a 5HT uptake inhibitor. Such diseases include depression, substance abuse and senile dementia. One or more 5HT uptake inhibitors together with a homopolymer or copolymer of N-vinyl pyrrolidone may be used in the treatment of such diseases.
Assignee NS- Name (City, State, Country);
CIPLA LTD (, , IN);
Assignee Original- Name (City, State, Country);
CIPLA LTD (, , IN);
Filing Date: 2002-9-2
PDF
Image
Claims Tree
Chem.Structure
Search Results
Refresh
Find
PN: GB2392385
AN: CIPLA LTD
TTL: Pharmaceutical preparations comprising a 5HT uptake inhibitor and a homopolymer or copolymer of N-vinyl pyrrolidone
ABST: Pharmaceutically acceptable preparations comprising one or more 5HT uptake inhibitors with an excipient matrix comprising a homopolymer or copolymer of N-vinyl pyrrolidone in which the 5HT
Validate and Add
inhibitors are preferably in amorphous form and may be selected from citalopram, venlafaxine, desmethyl venlafaxine, sertraline, fluoxetine and their salts. The homopolymer or copolymer is preferably a polyvinylpyrrolidone or crospovidone. The preparations are suitable for the treatment of a range of diseases which are prevented, ameliorated or eliminated by the administration of a 5HT uptake inhibitor. Such diseases include depression, substance abuse and senile dementia. One or more 5HT uptake inhibitors together with a homopolymer or copolymer of N-vinyl pyrrolidone may be used in the treatment of such diseases.
One can validate and highlight a particular chemical name of their interest from the dataset.
UDC1: citalopram, Formulation
PRI:
APD: 02-09-2002

Patent Viewer

Detailed View | Tabular View | Family View

Chemical Validation

You have selected N-vinyl pyrrolidone to be added.

Check Name

Chemical Structure

The selected N-vinyl pyrrolidone is valid



All occurances of selected N-vinyl pyrrolidone across all patents will be recognized and added.

Add to Report

G ... e inhibitor and a homopolymer or copolymer of N-vinyl pyrrolic

Look In: All

Right cl

Patent

EP017
EP034
EP047
EP071
EP109
EP112
EP115
EP116
EP128
EP148
EP150
EP172
EP177
GB237
GB237
GB239
JP200
JP200
JP200
JP200
US20020187929
US20030208687

Family Members:

Show Family

... Fields | Edit | Title | Abstract

...inhibitor and a

...ing one or ...g a 5HT uptake . The 5HT ...be selected ...e, fluoxetine ...a ...itable for the ...rated or ...ch diseases ...One or more ...mer of N-vinyl

Assignee Original- Name (City, State, Country);
CIPLA LTD (, , IN);

Filing Date: 2002-9-2

Issue/Publication Date: 2004-3-3

Kind Code: A

Comments:

PDF | Image | Claims Tree | Chem.Structure | Search Results

Refresh | Fin...

PN:	GB2392385
AN:	CIPLA LTD
TTL:	Pharmaceutical preparations comprising a 5HT uptake inhibitor and a homopolymer or copolym of N-vinyl pyrrolidone
ABST:	Pharmaceutically acceptable preparations comprising one or more 5HT uptake inhibitors an excipient matrix comprising a homopolymer copolymer of N-vinyl pyrrolidone in which the 5 uptake inhibitors are complexed with the homopolymer or copolymer. The 5HT uptake inhibitors are preferably in amorphous form an may be selected from citalopram, venlafaxine, desmethyl venlafaxine, sertraline, fluoxetine an their salts. The homopolymer or copolymer is preferably a polyvinylpyrrolidone or crospovidor The preparations are suitable for the treatment a range of diseases which are prevented, ameliorated or eliminated by the administration a 5HT uptake inhibitor. Such diseases include depression, substance abuse and senile demer One or more 5HT uptake inhibitors together wi homopolymer or copolymer of N-vinyl pyrrolido may be used in the treatment of such diseases
ACLM:	
SPEC:	
CMT:	
UDC1:	citalopram, Formulation


citalopram_2007-08-28 01:03:45 - [Patent iNSIGHT Pro - CHEMPAT Full Edition]
File Tools Help
Close Report
Add Patents
Custom Fields
Refresh
Clear Filter
F/R Scor_ Patent
EP0171943
EP0347066
EP0474580
EP0714663
EP1095926
EP1125907
EP1152000
EP1169314
EP1288211
EP1486492
EP1502907
EP1726298
EP1777221
GB2376233
GB2376945
GB2392385
JP200211477
Field Selection
Patent Details Column
Image
Abstract
Assignee Original
Assignee NS
Inventor Original
Inventor NS
Filing Date
Issue/Publication Date
Priority Date
Priority Details
Kind Code
Application No
US Classes (UPC)
International Classes (IPC)
European Classification (ECLA)
Field of Search
Attorney
Primary Examiner
Assistant Examiner
No of Claims
Full Claims
Independent Claims Count
Independent Claims
Unique Family Reference No
Family Patents
Family Countries
US Backward Citations
Forward Citations
Non-US Backward Citations
Domestic Backward Citation Count
Custom Field:
Custom Field are not present
UDC:
UDC1
Global Score:
Score1
Local Score:
Local Scores are not present
Image:
Front page Drawing
Front Page
Claims Page
Chemical Structures (ALL)
Chemical Structures (TA)
Chemical Structures (Claim)
Chemical Structures (Description)
<< Back
Next >>
Finish
Cancel
We can even export the structures along with the other patent data in to word & excel files and save it on the hard disk.

2. WO0039112: METHOD FOR THE PREPARATION OF 5-CYANOPHTHALIDE

TA Chemical Structures:

 amide	 ammonia	 citalopram
 ester		
		R1

adf [Compatibility Mode] - Microsoft Excel

Home | Insert | Page Layout | Formulas | Data | Review | View

Paste | Clipboard | Arial | 9 | Font | Alignment | General | Number | Conditional Formatting | Format as Table | Cell Styles | Styles | Insert | Delete | Format | Cells | Sort & Filter | Find & Select | Editing

A1 | Patent Number

	A	B	C	D	E
1	**Patent Number**	**Title**	**Chemical Structures**		
2	WO0023431	METHOD FOR THE PREPARATION OF CITALOPRAM	carboxy; TA	citalopram; TA	thiazoline; T











Sheet1 | InfoSheet

CHEMPAT Edition – Key Advantages

1. Identification of the chemical structure present within a set of patents is much faster and easier.

2. By using substructure search option one can determine the relevant patent for prior art searching.

3. Side by side claims and structure analysis in TAC view helps in quick identification of most relevant patents.

4. Saved structures can exported in variety of formats for use in various other softwares

5. Exporting the structures in word and excel will be very helpful in analyzing the patents and for presentation purpose..

Contact us today for a personalized demo

sales@patentinsightpro.com

+1-866-716-1507
+44-20-32862300
+91.22.32208312

Patent iNSIGHT Pro
Transform Patents to Intelligence